3 FTSE Shares You Should Have Bought Last Week: Mulberry Group PLC, Hargreaves Lansdown plc and Hikma Pharmaceuticals Plc

The FTSE 100 (INDEXFTSE:UKX) got trounced this week by Mulberry Group PLC (LON: MUL), Hargreaves Lansdown plc (LON: HL) and Hikma Pharmaceuticals Plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Last week the FTSE 100 (FTSEINDICES: ^FTSE) closed down 185 points, or 2.75%, on the start of the week. Investors were spooked ahead of the referendum in Crimea and economic data indicated a slowdown in China.

If you kept your nerve and bought shares — a great business is still a great business, no matter what market sentiment is — then you might have picked up a bargain or two.

Here are some of the top risers:

Mulberry 

MulberryShares in Mulberry (LSE:  MUL) hiked 5% this week after the chief executive, Bruno Guillon, resigned after serving two years in the role. His tenure had not been successful.

Earlier this year Mulberry’s shares plunged 24% after announcing another profit warning. Guillon stated at the time that the company “continues to invest in the ongoing process of transforming Mulberry from a domestic to a global luxury brand.”

That was his failing. The result of this strategy was a steep hike in prices, that put off consumers. Mulberry has been rudderless for some time after the brand’s creative director, Emma Hill, resigned last summer in opposition to the new direction.

Mulberry’s previous success was based on designs that were expensive, but not out of reach, for many British shoppers. Even in 2009, during the recession, UK sales improved 40%.

Today? Nobody’s buying a Mulberry bag that costs upwards of £1,000. Instead, customers have defected to cheaper brands such as Coach and Michael Kors.

Godfrey Davis, the company’s chairman, will take over until a successor is found.

Hargreaves Lansdown

_ISA2Hargreaves Lansdown (LSE: HL) was a big beneficiary from George Osborne’s Budget announcement on Wednesday. The shares are up 11% since the beginning of the week.

The gains came at the expense of leading insurers, such as Aviva and Legal & General — which fell 11% and 7% respectively — after it was announced that pensioners will no longer require an annuity to remove money from their pension pot.

Hargreaves Lansdown, the UK’s largest investment platform, should receive an upswing in business as pensioners take their savings as a lump sum and invest money in the stock market.

A similarly favourable news snippet was the announcement that ISAs, which currently exist in two forms — cash and stocks — will be merged into a single “New ISA” with a higher annual savings limit of £15,000. Hargreaves sells ISAs, and again, will benefit here.

Hikma Pharmaceuticals

astrazenecaAnalysts were widely predicting Hikma Pharmaceuticals’ (LSE: HIK) final results would show a 90% earnings increase. The shares have been thriving on these expectations.

When the official figures were unveiled they smashed the forecasts, coming in at 111%, and the share price has increased 7% on last week.

Since the beginning of the year Hikma’s gains have more than tripled the leading blue-chip pharma companies GlaxoSmithKline and AstraZeneca combined. Being a smaller company, Hikma Pharmaceuticals is potentially a more attractive growth stock than its larger brethren.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Mark does not own shares in any company mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »